00874 BAIYUNSHAN PH
- 19.440
- +0.740+3.96%
BAIYUNSHAN PH News
baiyunshan (600332.SH) distributed 0.4 yuan per share in the first half of the year, with the record date of October 24th.
Baiyunshan (600332.SH) announced that the company will implement the mid-year equity distribution in 2024, with a distribution of...
Guangzhou Baiyunshan Pharmaceutical Branch Gets Supplementary Drug Application for Antibiotic
Baiyunshan ph (600332.SH): Its subsidiary obtained the supplementary application approval for chemical raw materials active pharmaceutical ingredient.
On October 15, Gelonghui reported that Baiyunshan Pharmaceuticals (600332.SH) announced that its subsidiary, Baiyunshan Pharmaceutical Group Co., Ltd., Baiyunshan Chemical Pharmaceuticals Factory (referred to as "Baiyunshan Chemical Pharmaceuticals Factory"), received the "Chemical Raw Materials Supplementary Application Approval Notice" issued by the National Medical Products Administration. Cefuroxime Sodium is used for the following infections caused by sensitive bacteria: respiratory tract infections, otolaryngology infections, urinary tract infections, skin and soft tissue infections, sepsis, meningitis, gonorrhea, bone and joint infections, etc.
baiyunshan (00874.HK) received approval from the National Pharmaceutical Regulatory Agency for the issuance of the 'Drug Registration Certificate' for Tadalafil Tablets (10mg).
Gelonghui October 14 | Pharmaceutical company baiyunshan (00874.HK) announced that recently, the Baiyunshan Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") subsidiary Baiyunshan Pharmaceutical Group Co., Ltd. Baiyunshan Pharmaceutical Factory (hereinafter referred to as "Baiyunshan Pharmaceutical Factory") received the "Pharmaceutical Registration Certificate" approved and issued by the National Medical Products Administration for Tadalafil tablets (10mg). Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor, mainly used to treat male erectile dysfunction (ED). It was originally researched by Eli Lilly and Company, approved in November 2002 and January 2003 respectively.
Baiyunshan (00874.HK) held a board of directors meeting on October 25 to review and approve the performance of the first three quarters.
Galaxy Today, October 14th, baiyunshan (00874.HK) announced that it will hold a board of directors meeting on October 25, 2024 (Friday) to review and approve the unaudited financial performance of the company and its subsidiaries for the nine months ended September 30, 2024, and deal with other matters (if any).
BAIYUNSHAN PH: DATE OF BOARD MEETING
Baiyunshan (600332.SH): Subsidiary pharmaceutical products pass generic drug consistency evaluation.
On October 11, Gelonghui reported that Baiyunshan (600332.SH) announced that its holding subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (referred to as "Tianxin Pharmaceutical"), has received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration. The injection cephalosporin sodium (0.5g, 1.0g) has passed the generic drug quality and efficacy consistency evaluation. Cefuroxime sodium is a first-generation cephalosporin and a frontline clinical anti-infective drug, suitable for the treatment of infections caused by sensitive bacteria such as otitis media, bronchitis, pneumonia, respiratory tract infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, etc.
Are Robust Financials Driving The Recent Rally In Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock?
Baiyunshan (00874.HK) shares were reduced by 0.186 million shares by Norges Bank.
According to the latest equity disclosure information from the Hong Kong Stock Exchange on September 30, 2024, baiyunshan ph (00874.HK) was reduced by Norges Bank on the exchange at an average price of HK$20.6237 per share, reducing 0.186 million shares, involving approximately HK$3.836 million. After the reduction, Norges Bank's latest number of shares held is 35.095 million shares, and the shareholding percentage has decreased from 16.04% to 15.96%.
BAIYUNSHAN PH: (1) POLL RESULTS OF THE SECOND EXTRAORDINARY GENERAL MEETING IN 2024 HELD ON 27 SEPTEMBER 2024; AND (2) PAYMENT OF INTERIM DIVIDEND FOR THE SIX MONTHS ENDED 30 JUNE 2024
BAIYUNSHAN PH: Interim Report 2024
Baiyunshan (600332.SH): Pharmaceutical products of its subsidiary have passed the consistency evaluation of generic drugs.
GeLongHui September 18th, baiyunshan (600332.SH) announced that its subsidiary, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. Baiyunshan Pharmaceutical Factory (referred to as “Baiyunshan Pharmaceutical Factory”), has received the 'Drug Supplementary Application Approval Notice' issued by the National Medical Products Administration. The Azithromycin Capsules have passed the generic drug quality and efficacy consistency evaluation. Azithromycin belongs to the macrolide antibiotics category, with characteristics such as a broad spectrum of antibacterial activity, fast oral absorption, and a long half-life. It is mainly used to treat: (1) Acute pharyngitis and acute tonsillitis caused by Staphylococcus aureus; (2) Sinusitis caused by susceptible bacteria,
HK stock news | Baiyunshan (00874) fell more than 3%, second quarter performance under pressure, and Morgan Stanley lowered the company's profit expectations and target price.
Baiyunshan (00874) fell more than 3%, as of the time of writing, it fell 3.02%, to HK$16.7, with a turnover of HK$2.9731 million.
Daiwa: maintains the 'in line with the market' rating for baiyunshan (00874), with a target price lowered to 21.7 Hong Kong dollars.
Deutsche Bank has lowered its profit expectations for Baiyunshan from 2024 to 2030 by 3%-11%.
The Past Five Years for Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Investors Has Not Been Profitable
Guangzhou Baiyunshan Pharmaceutical Gets License to Expand Unit's Drug Production License
Hong Kong stock announcement | Two national-level specialized, special and new "little giant" enterprises added to circ
Wuxi AppTec (02359) plans to repurchase 1 billion yuan of A shares to further maintain the company's value and shareholder rights; Baiyunshan (00874): glyceryl trinitrate injection has passed the generic drug quality and efficacy consistency evaluation.
Baiyunshan Pharma Gets China Supplemental Drug Nod for Nitroglycerin Injection for Heart Problems
Baiyunshan (600332.SH): Nitroglycerin Injection Passes Generic Drug Consistency Evaluation.
On September 10th, Baiyunshan (600332.SH) announced that its wholly-owned subsidiary, Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd., has received the Drug Supplementary Application Approval Notice issued by the National Medical Products Administration. The Nitroglycerin Injection (specification: 1ml:5mg) has passed the evaluation of generic drug quality and therapeutic efficacy consistency. Nitroglycerin Injection can be used for blood pressure control in patients during cardiac or surgical procedures, or for the treatment of unstable angina and concealed congestive heart failure.
Baiyunshan ph (00874) received the "Pharmaceutical Production License" approved and issued by the Guangdong Pharmaceutical Supervision Administration.
Baiyunshan (00874) announced that its wholly-owned subsidiary, Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd. (also known as...
Analysis
Price Target
No Data
No Data